NYSE:CRL
Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.'s revenue fell 0.9% in fiscal 2025 to $4.0B while operating margin fell to 0.6%, its lowest in 10 years. Free cash flow was $518.5M, 12.9% of revenue, and the diluted share count fell 4.0%.Summary generated from Charles River Laboratories International, Inc.'s SEC filings. Latest annual report filed Feb 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.0B
Revenue growth−0.9%
Revenue, 5-yr CAGR+6.5%
Gross marginn/a
Operating margin0.6%
Net margin−3.6%
ROIC0.4%
Return on equity−4.4%
Debt / equity0.68
Free cash flow$518.5M
FCF margin12.9%
Share count change−4.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 |
| Operating income | 590 | 651 | 617 | 227 | 25 |
| Net income | 391 | 486 | 475 | 22 | −144 |
| Free cash flow | 532 | 295 | 365 | 502 | 518 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KRegulation FD disclosure
Sep 24, 2026 - 10-QQuarterly report for the period ended Jun 27, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
May 11, 2026 - 10-QQuarterly report for the period ended Mar 28, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026